US Patent Family Members and Approved Drugs for Australia Patent: 1516295
✉ Email this page to a colleague
US Patent Family Members and Approved Drugs for Australia Patent: AU1516295
| US Patent Number | Estimated Patent Expiration | Generic Name | US Applicant | US Tradename |
|---|---|---|---|---|
| 6,290,961 | 2013-12-28 | rimabotulinumtoxinb | Solstice Neurosciences, Llc | MYOBLOC |
| 6,290,961 | 2013-12-28 | alemtuzumab | Genzyme Corporation | CAMPATH |
| 6,632,433 | 2013-12-28 | rimabotulinumtoxinb | Solstice Neurosciences, Llc | MYOBLOC |
| 6,632,433 | 2013-12-28 | alemtuzumab | Genzyme Corporation | CAMPATH |
| 6,683,049 | 2013-12-28 | onabotulinumtoxina | Allergan, Inc. | BOTOX COSMETIC |
| 6,887,476 | 2013-12-28 | rimabotulinumtoxinb | Solstice Neurosciences, Llc | MYOBLOC |
| >US Patent Number | >Estimated Patent Expiration | >Generic Name | >US Applicant | >US Tradename |
